Novel inhibition of cancer cell growth in gastrointestinal cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1056170

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This research project will focus on new treatment targets for gastrointestinal malignancies, focusing on the mTOR pathway which is important in driving cancer cell growth. The mTOR inhibitor drug Everolimus will be used in colon and biliary tract cancers to look for novel biomarkers of response and resistance to treatment, using cancer cell lines and correlative analysis with data obtained from patients' tumour samples and clinical assessment in current trials.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2014

Funding Scheme: Postgraduate Scholarships

Funding Amount: $47,474.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Cell Biology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | cancer research | drug sensitivity | mutation screening | targeted therapy

Related Links